Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2006

01-07-2006

Surgical Outcomes of Noninvasive and Minimally Invasive Intraductal Papillary-Mucinous Neoplasms of the Pancreas

Authors: Hidenori Takahashi, MD, Shoji Nakamori, MD, Shin Nakahira, MD, Masanori Tsujie, MD, Yuji Takahshi, MD, Shigeru Marubashi, MD, Atsushi Miyamoto, MD, Yutaka Takeda, MD, Hiroaki Nagano, MD, Keizo Dono, MD, Koji Umeshita, MD, Masato Sakon, MD, Morito Monden, MD

Published in: Annals of Surgical Oncology | Issue 7/2006

Login to get access

Abstract

Background

Noninvasive and minimally invasive intraductal papillary-mucinous neoplasms (IPMNs) have a favorable surgical outcome. However, cases of recurrent noninvasive or minimally invasive IPMN are sometimes encountered, and the patterns of the recurrence of those tumors have not yet been fully clarified. In this study, we evaluated the surgical outcome of noninvasive and minimally invasive IPMNs, concentrating particularly on the pattern of recurrences.

Methods

Twenty patients with noninvasive and minimally invasive IPMNs were assessed. Resected specimens were evaluated histopathologically with regard to the malignant nature of the tumors, the status of the surgical margin, and peripancreatic lymph node involvement. Cumulative overall survival rates and recurrence after surgery were assessed.

Results

Of the 20 patients, 13 had benign IPMNs, including adenomas (n = 10) and borderlines (n = 3), and 7 had malignant IPMNs, including carcinomas in situ (n = 4) and minimally invasive IPMNs (n = 3). Histopathologic examination confirmed the absence of tumor involvement in the resected lymph nodes and at the surgical margins. During the follow-up period, one patient with minimally invasive IPMN and one patient with noninvasive IPMN died of tumor recurrence in the peritoneum that was presumably caused by intraoperative manipulation. All of the patients with benign IPMNs survived, whereas the 10-year survival rate of the patients with malignant IPMNs was 67%.

Conclusions

Surgical resection can offer a favorable outcome for noninvasive and minimally invasive IPMNs. Tumor recurrence was observed only in the peritoneal cavity. More careful perioperative management concerned with peritoneal recurrence should be emphasized for noninvasive and minimally invasive IPMNs.
Literature
1.
Kimura W, Sasahira N, Yoshikawa T, Muto T, Makuuchi M. Duct-ectatic type of mucin producing tumor of the pancreas—new concept of pancreatic neoplasia. Hepatogastroenterology 1996;43:692–709PubMed
2.
Rickaert F, Cremer M, Deviere J, et al. Intraductal mucin-hypersecreting neoplasms of the pancreas. A clinicopathologic study of eight patients. Gastroenterology 1991;101:512–9PubMed
3.
Furukawa T, Takahashi T, Kobari M, Matsuno S. The mucus-hypersecreting tumor of the pancreas. Development and extension visualized by three-dimensional computerized mapping. Cancer 1992;70:1505–13PubMed
4.
Sohn TA, Yeo CJ, Cameron JL, Iacobuzio-Donahue CA, Hruban RH, Lillemoe KD. Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg 2001;234:313–21; discussion 321–2PubMedCrossRef
5.
Klöppel G, Solcia E, Longnecker DS, Capella C, Sobin LH, eds. Histologic Typing of Tumors of the Exocrine Pancreas. 2nd ed. Geneva: Springer-Verlag, 1996
6.
Cuillerier E, Cellier C, Palazzo L, et al. Outcome after surgical resection of intraductal papillary and mucinous tumors of the pancreas. Am J Gastroenterol 2000;95:441–5PubMedCrossRef
7.
Doi R, Fujimoto K, Wada M, Imamura M. Surgical management of intraductal papillary mucinous tumor of the pancreas. Surgery 2002;132:80–5PubMedCrossRef
8.
Japan Pancreatic Society Classification of Pancreatic Carcinoma. 1st English ed. Tokyo: Kanehara & Co Ltd, 1996
9.
Nakagohri T, Asano T, Kenmochi T, Urashima T, Ochiai T. Long-term surgical outcome of noninvasive and minimally invasive intraductal papillary mucinous adenocarcinoma of the pancreas. World J Surg 2002;26:1166–9PubMedCrossRef
10.
Chari ST, Yadav D, Smyrk TC, et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology 2002;123:1500–7PubMedCrossRef
11.
Sho M, Nakajima Y, Kanehiro H, et al. Pattern of recurrence after resection for intraductal papillary mucinous tumors of the pancreas. World J Surg 1998;22:874–8PubMedCrossRef
12.
Terris B, Ponsot P, Paye F, et al. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol 2000;24:1372–7PubMed
13.
Horvath KD, Chabot JA. An aggressive resectional approach to cystic neoplasms of the pancreas. Am J Surg 1999;178:269–74PubMedCrossRef
14.
Kobari M, Egawa S, Shibuya K, et al. Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: differences in clinical characteristics and surgical management. Arch Surg 1999;134:1131–6PubMedCrossRef
15.
Ishikawa O, Ohigashi H, Nakamori S, et al. Three-segmental cytodiagnosis using balloon catheter for locating occult carcinoma of the pancreas. J Am Coll Surg 1995;180:353–5PubMed
16.
Nakagohri T, Kenmochi T, Kainuma O, Tokoro Y, Kobayashi S, Asano T. Inferior head resection of the pancreas for intraductal papillary mucinous tumors. Am J Surg 2000;179:482–4PubMedCrossRef
17.
Raimondo M, Tachibana I, Urrutia R, Burgart LJ, DiMagno EP. Invasive cancer and survival of intraductal papillary mucinous tumors of the pancreas. Am J Gastroenterol 2002;97:2553–8PubMedCrossRef
18.
Adsay NV, Conlon KC, Zee SY, Brennan MF, Klimstra DS. Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients. Cancer 2002;94:62–77PubMedCrossRef
Metadata
Title
Surgical Outcomes of Noninvasive and Minimally Invasive Intraductal Papillary-Mucinous Neoplasms of the Pancreas
Authors
Hidenori Takahashi, MD
Shoji Nakamori, MD
Shin Nakahira, MD
Masanori Tsujie, MD
Yuji Takahshi, MD
Shigeru Marubashi, MD
Atsushi Miyamoto, MD
Yutaka Takeda, MD
Hiroaki Nagano, MD
Keizo Dono, MD
Koji Umeshita, MD
Masato Sakon, MD
Morito Monden, MD
Publication date
01-07-2006
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 7/2006
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/ASO.2006.05.043

Other articles of this Issue 7/2006

Annals of Surgical Oncology 7/2006 Go to the issue

OriginalPaper

Initial Outcomes for Patients Treated on the American Society of Breast Surgeons MammoSite Clinical Trial for Ductal Carcinoma-In-Situ of the Breast

OriginalPaper

Activated Akt and Erk Expression and Survival After Surgery in Pancreatic Carcinoma

OriginalPaper

Local Recurrences After Conservative Treatment of Ductal Carcinoma-In-Situ of the Breast Without Radiotherapy: The Effect of Age

OriginalPaper

PIK3CA and TFRC Located in 3q Are New Prognostic Factors in Esophageal Squamous Cell Carcinoma

OriginalPaper

Three–Axillary Lymph Node Sampling for the Prediction of Nonsentinel Node Metastases in Breast Cancer Patients With Sentinel Node Metastases

OriginalPaper

Galectin 7 (p53-Induced Gene 1): A New Prognostic Predictor of Recurrence and Survival in Stage IV Hypopharyngeal Cancer